Skip to search formSkip to main contentSkip to account menu

2 ML denileukin diftitox 0.15 MG/ML Injection

Known as: denileukin diftitox 300 MCG in 2 ML Injection, denileukin diftitox 300 MCG per 2 ML Injection 
National Institutes of Health

Related topics

Related topics

10 relations
DENILEUKINDecreased Protein Synthesis [PE]Diphtheria ToxinDrug Allergy

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Targeted therapies: Denileukin diftitox—a step towards a 'magic bullet' for CTCL
Investigators found that denileukin diftitox, which targets the interleukin-2 receptor, achieves objective response rates in 44… 
2008
2008
Denileukin diftitox
  • 2008
  • Corpus ID: 263362170
2008
2008
Response to correspondence: Denileukin diftitox vision loss not due to posterior ischemic optic neuropathy
We are glad that our article ‘‘Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic… 
Review
2008
Review
2008
Long term Complete Response to Denileukin Diftitox and Bexarotene
Madeleine Duvic, MD, is Professor of Internal Medicine and Dermatology, and Deputy Chairman of the Department of Dermatology at… 
2007
2007
Denileukin diftitox and vision loss
Denileukin diftitox (DD) is a novel immunotoxin approved in the USA for the treatment of relapsed CD25 positive cutaneous T-cell… 
2006
2006
Denileukin diftitox
  • 2006
  • Corpus ID: 262330978
2000
2000
Denileukin Diftitox: A Viewpoint by Madeleine Duvic
1998
1998
USAN Council. List No.405. New names. Denileukin Diftitox.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)